SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

Published:2019-10 Issue:10 Volume:14 Page:1847-1852
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Aggarwal Charu,Redman Mary W.,Lara Primo N.,Borghaei Hossein,Hoffman Philip,Bradley Jeffrey D.,Newman Alfred J.,Feldman Marvin J.,Minichiello Katherine,Miao Jieling,Mack Philip C.,Papadimitrakopoulou Vassiliki A.,Herbst Roy S.,Kelly Karen,Gandara David R.

Funder

Millennium

GlaxoSmithKline

Genentech

Janssen Biotech

Merck

Bristol-Myers Squibb

Lilly

Celgene

Boehringer Ingelheim

Novartis

Astra Zeneca

F. Hoffman–La Roche

F. Hoffmann-La Roche

Takeda

AbbVie

Eli Lilly and Company

National Institutes of Health

National Cancer Institute

Amgen

Pfizer

National Institutes of Health

National Institutes of Health

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference6 articles.

1. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017

2. Comprehensive genomic characterization of squamous cell lung cancers;Nature,2012

3. Lung Master Protocol (Lung-MAP)—a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400;Herbst;Clin Cancer Res,2015

4. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family;Gavine;Cancer Res,2012

5. Identification of targetable FGFR gene fusions in diverse cancers;Wu;Cancer Discov,2013

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400);Journal of Thoracic Oncology;2024-08

2. Epithelial–mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC);Cancer Pathogenesis and Therapy;2024-07

3. Targeting FGFR for cancer therapy;Journal of Hematology & Oncology;2024-06-03

4. Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience;Diagnostics;2024-05-15

5. Novel therapeutic strategies for rare mutations in non-small cell lung cancer;Scientific Reports;2024-05-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3